The introduction of new medical products and technologies presents both opportunity and risk for IDNs. Without a structured approach to new product entry, supply chains can face uncontrolled spend, clinical variability, and adoption of innovations that fail to deliver promised value. In this session, explore how leading IDNs are building frameworks for evaluating, introducing, and monitoring new products while maintaining the agility needed to embrace genuine clinical advancement.

Hear from supply chain leaders who have successfully implemented new product entry processes that balance innovation with evidence-based decision-making, physician engagement, and financial stewardship.

Learning Objectives:
1. Recognize the key components of an effective new product entry process, from initial request through evaluation, trial, and full adoption or rejection.
2. Apply evaluation criteria that assess clinical evidence, cost-effectiveness, and alignment with organizational priorities when reviewing new product requests.
3. Develop strategies for engaging physicians and clinical stakeholders in structured new product evaluation.
4. Design monitoring and feedback mechanisms that track new product performance post-introduction to ensure sustained value delivery and inform future decisions.